Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Thierry AR, et al. Among authors: robert b. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23. Nat Med. 2014. PMID: 24658074
High fragmentation characterizes tumour-derived circulating DNA.
Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, Thierry AR. Mouliere F, et al. Among authors: robert b. PLoS One. 2011;6(9):e23418. doi: 10.1371/journal.pone.0023418. Epub 2011 Sep 6. PLoS One. 2011. PMID: 21909401 Free PMC article.
Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer.
Jeitany M, Leroy C, Tosti P, Lafitte M, Le Guet J, Simon V, Bonenfant D, Robert B, Grillet F, Mollevi C, El Messaoudi S, Otandault A, Canterel-Thouennon L, Busson M, Thierry AR, Martineau P, Pannequin J, Roche S, Sirvent A. Jeitany M, et al. Among authors: robert b. EMBO Mol Med. 2018 Apr;10(4):e7918. doi: 10.15252/emmm.201707918. EMBO Mol Med. 2018. PMID: 29438985 Free PMC article.
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Assenat E, et al. Among authors: robert b. Oncotarget. 2015 May 20;6(14):12796-808. doi: 10.18632/oncotarget.3473. Oncotarget. 2015. PMID: 25918250 Free PMC article. Clinical Trial.
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. Thomas G, et al. Among authors: robert b. Oncotarget. 2014 Aug 30;5(16):7138-48. doi: 10.18632/oncotarget.2231. Oncotarget. 2014. PMID: 25216528 Free PMC article.
610 results